Perceptic secures $12m in seed funding led by Accel to expand its pharmaceutical artificial intelligence platform.
The London-based company raised capital from Accel, Air Street Capital, and Elder Gull to grow its engineering team and scale deployments.
≈ £8.9M at $1 = £0.7454 on 27 May 2026
Perceptic builds a unified artificial intelligence platform designed to connect the entire drug development lifecycle for pharmaceutical companies.
Perceptic has secured $12m in a seed funding round led by Accel, alongside participation from Air Street Capital and Elder Gull. The capital will be directed towards growing the engineering team and scaling current production deployments across the pharmaceutical sector.
Founded in London in 2024 by former Palantir engineers Tilman Flock, Martin Copes, and Zaki Trache, the company developed a shared intelligence layer that integrates data from early discovery through to clinical development. Perceptic already operates paid production deployments with major industry participants including CSL.
The investment arrives as the global artificial intelligence in drug discovery market experiences rapid expansion, with backers noting the platform addresses the fragmented nature of pharmaceutical research by following the asset rather than individual departments.
From the founder
"Too many critical drug development decisions still happen without a complete view of the evidence. Perceptic connects data, context, and decision-making so every insight compounds instead of dying at the next handoff."
Tilman Flock
Co-founder at Perceptic
Investor perspective
"Perceptic is the first solution that follows the drug rather than the department. The founders combine deep life sciences expertise with real experience deploying AI at scale."
Sonali De Rycker
Partner, Accel
Use of funds
- 01Grow the team
- 02Expand into international markets
